Neurocrine Biosciences | NBIX - Loan Capital


Neurocrine Biosciences reported $169.5M in Loan Capital for its fiscal quarter ending in March of 2023.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.48B 7.23M Jun/2026
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Cytokinetics USD 248.2M 993K Jun/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 60.5B 70M Jun/2026
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Repligen USD 551.05M 4.46M Jun/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Teva Pharmaceutical Industries USD 12.09B 1.92B Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025